Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 1-13

  Lancaster, Jason W ^a   Matthews, S James ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Clostridium spp; Diarrhea; Fidaxomicin; Treatment

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

ABDOMINAL PAIN; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BIOSIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DIZZINESS; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; EMBASE; ENTEROCOCCUS; GASTROINTESTINAL HEMORRHAGE; HUMAN; MEDLINE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUTROPENIA; PHARMACODYNAMICS; RASH; REVIEW; SINGLE DRUG DOSE; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; VOMITING;

AMINOGLYCOSIDES; ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DRUG COSTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; RECURRENCE; TREATMENT OUTCOME;

EID: 84856194482     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.003     Document Type: Review

References (72)

1. Dificid [package insert] 2011, Optimer Pharmaceutics, San Diego, Calif.
2. Hubert B., Loo V.G., Bourgault A.M., et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. Clin Infect Dis 2007, 44:238-244.
3. Kuijper E.J., Coignard B., Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl 6):2-18.
4. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
5. McDonald L.C., Owings M., Jernigan D.B. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-415.
6. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
7. Kuijper E.J., Barbut F., Brazier J.S., et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008, 13:1-7.
8. Gerding D.N. Disease associated with Clostridium difficile infection. Ann Intern Med 1989, 110:255-257.
9. Lyerly D.M., Krivan H.C., Wilkins T.D. Clostridium difficile: its disease and toxins. Clin Microbiol Rev 1988, 1:1-18.
10. McFarland L.V., Stamm W.E. Review of Clostridium difficile-associated diseases. Am J Infect Control 1986, 14:99-109.
11. Grundfest-Broniatowski S., Quader M., Alexander F., et al. Clostridium difficile colitis in the critically ill. Dis Colon Rectum 1996, 39:619-623.
12. Kyne L., Merry C., O'Connell B., et al. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 1999, 28:107-113.
13. Lawrence S.J., Puzniak L.A., Shadel B.N., et al. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol 2007, 28:123-130.
14. Kyne L., Hamel M.B., Polavaram R., et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002, 34:346-353.
15. Ackermann G., Thomalla S., Ackermann F., et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea. J Med Microbiol 2005, 54:149-153.
16. Bartlett J.G. Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 1994, 18(Suppl 4):S265-S272.
17. Zilberberg M.D. Clostridium difficile-related hospitalizations among US adults, 2006. Emerg Infect Dis 2009, 15:122-124.
18. O'Brien J.A., Lahue B.J., Caro J.J., et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28:1219-1227.
19. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-2441.
20. Goncalves C., Decre D., Barbut F., et al. Prevalence and characterization of a binary toxin (actin-specific adp-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 2004, 42:1933-1939.
21. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
22. Gravel D., Miller M., Simor A., et al. Health care-associated clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study. Clin Infect Dis 2009, 48:568-576.
23. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31:431-455.
24. Vancocin [package insert] 2005, ViroPharma, Inc, Exton, Pa.
25. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
26. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-307.
27. Louie T., Gerson M., Grimard D., et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-Associated Diarrhea (CDAD). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill.
28. Baines S.D., O'Connor R., Freeman J., et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008, 62:1046-1052.
29. Al-Nassir W.N., Sethi A.K., Li Y., et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008, 52:2403-2406.
30. Sethi A.K., Al-Nassir W.N., Nerandzic M.M., et al. Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2009, 30:13-17.
31. Johnson A.P. New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert Opin Ther Pat 2010, 20:1389-1399.
32. Berman A.L. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2007, 41:932-933.
33. Herpers B.L., Vlaminckx B., Burkhardt O., et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009, 48:1732-1735.
34. Johnson S., Schriever C., Galang M., et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007, 44:846-848.
35. Juang P., Skledar S.J., Zgheib N.K., et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007, 35:131-137.
36. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
37. Musher D.M., Logan N., Mehendiratta V., et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007, 59:705-710.
38. Pepin J., Routhier S., Gagnon S., et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006, 42:758-764.
39. Coronelli C., White R.J., Lancini G.C., et al. Lipiarmycin, a new antibiotic from actinoplanes. Isolation, chemical, biological and biochemical characterization. J Antibiot 1975, 28:253-259.
40. Parenti F., Pagani H., Beretta G. Lipiarmycin, a new antibiotic from actinoplanes. Description of the producer strain and fermentation studies. J Antibiot 1975, 28:247-252.
41. Sergio S., Pirali G., White R., et al. Lipiarmycin, a new antibiotic from actinoplanes. Mechanism of Action. J Antibiot 1975, 28:543-549.
42. Gualtieri M., Villain-Guillot P., Latouche J., et al. Mutation in the bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006, 50:401-402.
43. Osburne M.S., Sonenshein A.L. Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis. J Virol 1980, 33:945-953.
44. Ackermann G., Loffler B., Adler D., et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004, 48:2280-2282.
45. Babakhani F., Gomez A., Robert N., et al. Postantibiotic effect of fidaxomicin and its major metabolite (OP-1118) against Clostridium difficile. Antimicrob Agents Chemother 2011, 55:4427-4429.
46. Babakhani F., Robert N., Shangle S., et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29 -November 2, 2004; Washington, DC.
47. Babakhani F., Seddon J., Robert N., et al. Narrow spectrum activity and low fecal protein binding of OPT-80 and its major hydrolysis metabolite (OP-1118). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill.
48. Citron D.M., Babakhani F., Goldstein E.J.C., et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009, 15:234-236.
49. Credito K.L., Appelbaum P.C. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004, 48:4430-4434.
50. Finegold S.M., Molitoris D., Vaisanen M.L., et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004, 48:4898-4902.
51. Hecht D.W., Galang M.A., Sambol S.P., et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007, 51:2716-2719.
52. Karlowsky J.A., Laing N.M., Alfa M., et al. In vitro antimicrobial activities of OPT-80, rifaximin, tigecycline, and comparators against toxin-positive Clostridium difficile cultured from diarrheal stool specimens. Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17- 20, 2007; Chicago, Ill.
53. Babakhani F., Gomez A., Robert N., et al. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol 2011, 60:1213-1217.
54. Biedenbach D.J., Ross J.E., Putnam S.D., et al. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 2010, 54:2273-2275.
55. Louie T.J., Emery J., Krulicki, et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009, 53:261-263.
56. Nerandzic M.M., Mullane K.M., Miller M.A., et al. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with either fidaxomicin (FDX) or vancomycin (VAN) for Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
57. Babakhani F., Shangle S., Robert N., et al. Resistance development, crossresistance, and synergy studies of OPT-80. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC.
58. Miller M., Mastrantonio P., Blanchette R., et al. Rifampin, rifaximin, OPT-80 and tigecycline susceptibility of C. difficile strains from Canada and Italy. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
59. Swanson R.N., Hardy D.J., Shipkowitz N.L., et al. In vitro and in vivo evaluation of tiacumicins b and c against Clostridium difficile. Antimicrob Agents Chemother 1991, 35:1108-1111.
60. Shue Y.K., Sears P.S., Shangle S., et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008, 52:1391-1395.
61. Louie T., Miller M., Donskey C., et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009, 53:223-228.
62. Louie T., Miller M., Crook D., et al. Effect of advancing age on outcomes of therapy for Clostridium difficile infection. Abstract presented at: Annual Scientific Meeting of the American Geriatrics Society; May 11-14, 2011; Washington, DC.
63. Crook D., Weiss K., Cornely O.A., et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin versus vancomycin. Abstract presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases, April 10-13, 2010; Vienna, Austria.
64. Mullane K., Golan Y., Crook D., et al. Renal impairment and response to fidaxomicin versus vancomycin in patients with clostridium difficile infection. Abstract presented at: 49th Annual meeting of the Infectious Diseases Society of America; October 20-23, 2011; Boston, Mass.
65. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364:422-431.
66. Cheknis A.K., Citron D.M., Nagaro K.J., et al. Epidemic BI/NAP1 is the dominant strain of Clostridium difficile found in patients in the OPT-80 vs. Vancomycin clinical trial in North American and the European Union. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC.
67. Golan Y., Mullane K.M., Miller M.A., et al. Low recurrence rate among patients with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
68. Gorbach S., Weiss K., Sears P., et al. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif.
69. Goldstein E.J., Citron D.M., Sears P., et al. Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection. Antimicrob Agents Chemother 2011, 55:5194-5199.
70. Mullane K.M., Miller M.A., Weiss K., et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 2011, 53:440-447.
71. Okumu F., Walsh R.B., Sears P., et al. Safety and pharmacokinetics of OPT- 80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC.
72. Drug Topics Red Book 2011, Thompson Medical Economics, Montvale, NJ.